178 related articles for article (PubMed ID: 9765623)
1. Differential expression of DNA topoisomerase II alpha and II beta genes between small cell and non-small cell lung cancer.
Syahruddin E; Oguri T; Takahashi T; Isobe T; Fujiwara Y; Yamakido M
Jpn J Cancer Res; 1998 Aug; 89(8):855-61. PubMed ID: 9765623
[TBL] [Abstract][Full Text] [Related]
2. Differential expression of DNA topoisomerases in non-small cell lung cancer and normal lung.
Giaccone G; van Ark-Otte J; Scagliotti G; Capranico G; van der Valk P; Rubio G; Dalesio O; Lopez R; Zunino F; Walboomers J
Biochim Biophys Acta; 1995 Dec; 1264(3):337-46. PubMed ID: 8547322
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous quantitation of topoisomerase II alpha and beta isoform mRNAs in lung tumor cells and normal and malignant lung tissue.
Mirski SE; Voskoglou-Nomikos T; Young LC; Deeley RG; Campling BG; Gerlach JH; Cole SP
Lab Invest; 2000 Jun; 80(6):787-95. PubMed ID: 10879730
[TBL] [Abstract][Full Text] [Related]
4. Comparison of DNA topoisomerase II alpha expression in small cell and nonsmall cell carcinoma of the lung. In search of a mechanism of chemotherapeutic response.
Guinee DG; Holden JA; Benfield JR; Woodward ML; Przygodzki RM; Fishback NF; Koss MN; Travis WD
Cancer; 1996 Aug; 78(4):729-35. PubMed ID: 8756364
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical detection of DNA topoisomerase IIalpha, P-glycoprotein and multidrug resistance protein (MRP) in small-cell and non-small-cell lung cancer.
Kreisholt J; Sorensen M; Jensen PB; Nielsen BS; Andersen CB; Sehested M
Br J Cancer; 1998 May; 77(9):1469-73. PubMed ID: 9652763
[TBL] [Abstract][Full Text] [Related]
6. Expression of DNA topoisomerase IIalpha and topoisomerase IIbeta genes predicts survival and response to chemotherapy in patients with small cell lung cancer.
Dingemans AM; Witlox MA; Stallaert RA; van der Valk P; Postmus PE; Giaccone G
Clin Cancer Res; 1999 Aug; 5(8):2048-58. PubMed ID: 10473085
[TBL] [Abstract][Full Text] [Related]
7. A truncated cytoplasmic topoisomerase IIalpha in a drug-resistant lung cancer cell line is encoded by a TOP2A allele with a partial deletion of exon 34.
Mirski SE; Sparks KE; Yu Q; Lang AJ; Jain N; Campling BG; Cole SP
Int J Cancer; 2000 Feb; 85(4):534-9. PubMed ID: 10699927
[TBL] [Abstract][Full Text] [Related]
8. Topoisomerase IIalpha gene expression is regulated by the p53 tumor suppressor gene in nonsmall cell lung carcinoma patients.
Liu D; Huang CL; Kameyama K; Hayashi E; Yamauchi A; Sumitomo S; Yokomise H
Cancer; 2002 Apr; 94(8):2239-47. PubMed ID: 12001123
[TBL] [Abstract][Full Text] [Related]
9. Expression and relationship between topoisomerase I and II alpha genes in tumor and normal tissues in esophageal, gastric and colon cancers.
Kim R; Ohi Y; Inoue H; Toge T
Anticancer Res; 1999; 19(6B):5393-8. PubMed ID: 10697567
[TBL] [Abstract][Full Text] [Related]
10. Validation of a polymerase chain reaction aided transcript titration assay (PATTY) for topoisomerase II in lung cancer samples.
Dingemans AM; Van Ark-Otte J; Smit EF; Postmus PE; Giaccone G
Anticancer Res; 2000; 20(5B):3549-54. PubMed ID: 11131661
[TBL] [Abstract][Full Text] [Related]
11. Expression of Y box-binding protein-1 correlates with DNA topoisomerase IIalpha and proliferating cell nuclear antigen expression in lung cancer.
Gu C; Oyama T; Osaki T; Kohno K; Yasumoto K
Anticancer Res; 2001; 21(4A):2357-62. PubMed ID: 11724293
[TBL] [Abstract][Full Text] [Related]
12. Topoisomerase II alpha content and topoisomerase II catalytic activity cannot explain drug sensitivities to topoisomerase II inhibitors in lung cancer cell lines.
Yamazaki K; Isobe H; Hanada T; Betsuyaku T; Hasegawa A; Hizawa N; Ogura S; Kawakami Y
Cancer Chemother Pharmacol; 1997; 39(3):192-8. PubMed ID: 8996519
[TBL] [Abstract][Full Text] [Related]
13. Expression of drug resistance-related genes in head and neck squamous cell carcinomas and normal mucosa.
Hirata S; Katoh O; Oguri T; Watanabe H; Yajin K
Jpn J Cancer Res; 2000 Jan; 91(1):84-90. PubMed ID: 10744048
[TBL] [Abstract][Full Text] [Related]
14. Topoisomerase IIalpha and other drug resistance markers in advanced non-small cell lung cancer.
Dingemans AC; van Ark-Otte J; Span S; Scagliotti GV; van der Valk P; Postmus PE; Giaccone G
Lung Cancer; 2001 May; 32(2):117-28. PubMed ID: 11325482
[TBL] [Abstract][Full Text] [Related]
15. Alterations in the topoisomerase II alpha gene, messenger RNA, and subcellular protein distribution as well as reduced expression of the DNA topoisomerase II beta enzyme in a mitoxantrone-resistant HL-60 human leukemia cell line.
Harker WG; Slade DL; Parr RL; Feldhoff PW; Sullivan DM; Holguin MH
Cancer Res; 1995 Apr; 55(8):1707-16. PubMed ID: 7712479
[TBL] [Abstract][Full Text] [Related]
16. [Expression and significance of DNA topoisomerase I (topo I) in small cell lung cancer].
Guo QS; Liu YX; Yu JM; Wang JL; Zhong WX; Liu XJ
Zhonghua Zhong Liu Za Zhi; 2007 Feb; 29(2):124-6. PubMed ID: 17645849
[TBL] [Abstract][Full Text] [Related]
17. Tirapazamine: a hypoxia-activated topoisomerase II poison.
Peters KB; Brown JM
Cancer Res; 2002 Sep; 62(18):5248-53. PubMed ID: 12234992
[TBL] [Abstract][Full Text] [Related]
18. Suramin inhibits the phosphorylation and catalytic activity of DNA topoisomerase II in human lung cancer cells.
Funayama Y; Nishio K; Takeda Y; Kubota N; Ohira T; Ohmori T; Ohta S; Ogasawara H; Hasegawa S; Saijo N
Anticancer Res; 1993; 13(6A):1981-8. PubMed ID: 8297104
[TBL] [Abstract][Full Text] [Related]
19. Gene expression of DNA topoisomerases I, II alpha and II beta and response to cisplatin-based chemotherapy in advanced ovarian carcinoma.
Cornarotti M; Capranico G; Bohm S; Oriana S; Spatti GB; Mariani L; Ballabio G; Zunino F
Int J Cancer; 1996 Aug; 67(4):479-84. PubMed ID: 8759604
[TBL] [Abstract][Full Text] [Related]
20. Small cell lung carcinoma exhibits greater phospholipase C-beta1 expression and edelfosine resistance compared with non-small cell lung carcinoma.
Strassheim D; Shafer SH; Phelps SH; Williams CL
Cancer Res; 2000 May; 60(10):2730-6. PubMed ID: 10825148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
